-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, 4D pharma announced that the company’s investigational microbiome-based therapy MRx0518, in combination with Merck & Co.
4D pharma develops live biotherapeutics, an emerging class of medicines that includes a living organism (such as bacteria)
This ongoing study is conducted in patients with metastatic solid tumors who have received multiple prior therapies
Currently, 20 patients with renal cell carcinoma have been enrolled in Part B of the trial, and 4 of the first 16 patients who could be evaluated achieved clinical benefit and achieved stable disease for at least 6 months
"Today's clinical results in renal cell carcinoma patients met the pre-specified primary efficacy endpoint
4D pharma plans to discuss with partners and the company's Genitourinary Cancer Advisory Board the next development path for MRx0518, which could lead to a potential pivotal clinical trial in patients with immune checkpoint inhibitor-refractory renal cell carcinoma
References:
[1] 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma.
